Navigation Links
FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
Date:7/20/2009

EAST HANOVER, N.J., July 21 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved Tekturna HCT((R)) (aliskiren and hydrochlorothiazide) tablets as initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals. Tekturna HCT is a single-pill combination of Tekturna((R)) (aliskiren), the first and only approved direct renin inhibitor, and the diuretic hydrochlorothiazide (HCTZ), one of the most commonly-used high blood pressure medications.

The FDA approval of Tekturna HCT as initial therapy was based on clinical trial data involving more than 2,700 patients, which showed that treatment with the combination of Tekturna and HCTZ offered greater blood pressure reductions than either drug alone.

"Up to 85% of patients will need more than one medication to reach their blood pressure goals," said Alan Gradman, MD, Cardiologist at The Western Pennsylvania Hospital and Professor of Medicine at Temple University. "This approval gives doctors the opportunity to aggressively treat their patients with a single-pill combination of the only approved drug, Tekturna, that works by directly targeting renin and decreasing the activity of the renin angiotensin aldosterone system (RAAS) and, HCTZ, a diuretic. This results in more significant blood pressure reductions, compared to taking either drug alone."

Hypertension affects nearly 74 million US adults and is a major risk factor for cardiovascular disease, the number one leading cause of death in the US. If left untreated, patients with high blood pressure are at risk for cardiovascular events such as stroke, heart attack and heart failure. Of US adults being treated, an estimated 36% are not at their blood pressure goals.

Current US treatment guidelines support the first-line use of combination therapy in appropriate high blood pr
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... REDWOOD CITY, Calif., Dec. 18, 2014 ... on the development of medical diagnostics based on ... of gas flow, today announced financial results for ... 30, 2014. "Following the completion of ... well positioned to maximize the recently initiated CoSense® ...
(Date:12/19/2014)... 2014   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... from its pivotal field study of AT-001 (Grapiprant), ... dogs with osteoarthritis.  In the study, dogs receiving ... were statistically significant compared to placebo (p<0.05) at ...
(Date:12/17/2014)... Alemania, December 17, 2014 Los ... con un alto nivel de gasto en investigación y ... 2013/14 (finalizado el 30 de septiembre de 2014) ZEISS ... 4.287 millones de euros (año anterior: 4.190 millones de ... desfavorables. Las ganancias (EBIT) crecieron un 14 por ciento, ...
Breaking Medicine Technology:Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS confirma su posición en un entorno difícil 2
... of, a Drug Target Function. A Study Performed by Sidec and ... Two Major Conformations ... Have Been Identified, STOCKHOLM, ... direct structural evidence of the molecular mechanism,of the Synaptic Vesicle protein ...
... CardioVascular,BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) today announces ... for its Phase II clinical,trial for the treatment of ... announcing additional sites as they open for,enrollment. For current ... heart trial, please visit http://www.cvbt.com ., In ...
Cached Medicine Technology:The First Direct Structural Evidence of SV2A has Been Revealed Thanks to Protein Tomography(TM), and Published in BBRC 2CVBT Announces First Site to Begin Patient Enrollment for Its Phase II Heart Trial 2
(Date:12/20/2014)... Office Urgent Care of Paramus, New Jersey has served the ... treated over 40,000 patients while carrying out their mission of ... Paramus area. , For 2015, the practice is proud ... board certified physicians: Christine Milosis MD, Sandra Ugras Rey DO, ... work tirelessly to carry out The Doctor’s Office Urgent ...
(Date:12/20/2014)... Atore, Inc, (San Francisco, CA CEO: Masashi ... focused portal on December 17th, 2014. , One ... US and Japan. , MERRY BIRTHDAY SITE : ... , MERRY BIRTHDAY MESSAGE is part of 5 future ... Features, Choose from thousands of stock photos to decorate ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 Developers of ... release of a new plugin for Final Cut Pro ... , “TranSlice Volume 5 allows users to create hand ... it.” Said Christina Austin, CEO of Pixel Film Studios. ... of professionalism while maintaining an easy to use interface.” ...
(Date:12/20/2014)... 2014 Parker & Sons, Inc. a ... of experience in contractor services announces reaching a milestone ... the homeowners of Arizona. Parker and Sons is comprised ... technicians that make customer service the number one priority. ... and started with one service vehicle and has since ...
(Date:12/19/2014)... It’s very easy to become overwhelmed with ... put to the wayside until Christmas and the New Year ... “itch” and that burning desire to just escape it all ... journey to Telluride with a no-fuss, affordable package. Montrose Days ... the resort, and ensure that all accommodations are met. Plus, ...
Breaking Medicine News(10 mins):Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 2Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 3Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2
... The American Society,for Therapeutic Radiology and Oncology is pleased ... been selected as the 2007 Survivor,Circle Award winner. Ms. ... cash prize on Sunday, October 28, 2007, at 8:00 ... Annual Meeting, which will,take place October 28 through November ...
... 16 The Center for the Internet & Digital,Medicine ... Eleanor,Herriman, MD, MBA, will chair a panel on Business ... at the 3rd Annual World,Healthcare Innovation and Technology Congress ... from 2 to 3 pm. CIDM develops and ...
... Moved Atlanta Office to Larger Space and Constructed New ... Outcomes Strategy ... ECLP ), The Outcomes Company(R), today announced,that it will move ... will take place over the next few months with,completion expected by ...
... for next-generation sensors, researchers have crafted a layered material ... manner nature never intended. , Refraction always bends light ... of a "bent" drinking straw when observed through the ... alternating layers of semiconductors (indium-gallium-arsenic and aluminum-indium-arsenic) acts as ...
... covered by current pediatric vaccine, making it tough to ... -- An emerging "superbug" that causes ear infections in ... be treated with an adult medication, researchers report. , ... strain of Streptococcus pneumoniae that caused ear ...
... Highlands Acquisition Corp.,(Amex: HIA.U), (the "Company") announced today that, ... units may elect to separately trade,the common stock and ... warrants will be quoted on the American Stock Exchange ... will continue to,trade on the American Stock Exchange under ...
Cached Medicine News:Health News:L.A. Breast Cancer Activist Honored With Survivor Circle Award 2Health News:L.A. Breast Cancer Activist Honored With Survivor Circle Award 3Health News:CIDM Collaborates With World Congress to Advance Dialog on Online Provider Networks at WHIT 3.0 2Health News:Eclipsys Announces Relocation of Corporate Headquarters to Atlanta, GA 2Health News:Ear Infections Linked to Drug-Resistant 'Superbug' 2Health News:Ear Infections Linked to Drug-Resistant 'Superbug' 3Health News:Ear Infections Linked to Drug-Resistant 'Superbug' 4Health News:Highlands Acquisition Corp. Announces Separate Trading of Common Stock and Warrants 2
Reusable, stainless steel trephine with handle....
Reusable, stainless steel trephine with handle....
Reusable, stainless steel trephine with handle....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Medicine Products: